unknown
Stage
2014
Founded
3
Investors
About
Develops needle-free, intranasal epinephrine (neffy™ / ARS-1) for the treatment of severe allergic reactions and anaphylaxis, aiming to provide a portable, easy-to-use alternative to injectable epinephrine. The company is focused on patient-friendly delivery solutions to address needle-related risks and ease of use.
Explore ARS Pharmaceuticals, Inc.'s full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.